Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

elacestrant dihydrochloride

(EH-lah-SES-trant dy-HY-droh-KLOR-ide)
A drug used to treat postmenopausal women and adult men with estrogen receptor-positive, HER2-negative breast cancer that has a mutation (change) in the ESR1 gene and is advanced or has spread to other parts of the body. It is used in patients whose disease got worse after treatment with at least one type of hormone therapy. Elacestrant dihydrochloride binds to proteins called estrogen receptors, which are found on some breast cancer cells. These proteins may cause cancer cells to grow. Elacestrant dihydrochloride blocks these proteins and may keep cancer cells from growing. It is a type of estrogen receptor antagonist. Also called Orserdu.
More Information
Search NCI's Dictionary of Cancer Terms